Japan’s Takeda Pharmaceutical Co Ltd said on Monday the U.S. Food and Drug Administration had granted ‘fast track’ status to its vaccine for the mosquito-borne Zika virus, which erupted as a major public hazard in Brazil three years ago.
The drug, TAK-426, is currently being tested on 240 patients between the ages of 18 and 49 and is in early stages of development. The virus might be responsible for an increase in birth defects in the United States and its territories, the U.S. Centers for Disease Control and Prevention said in a report last week.
The Zika outbreak was declared an international public health emergency by the World Health Organization in 2016 due to linkages found between the virus and severe birth defects.
The FDA’s ‘fast track’ designation aims to facilitate the development and expedite the review process for certain drugs and vaccines for serious conditions with unmet medical need.
Japan’s Takeda Pharmaceutical Co Ltd said on Monday the U.S. Food and Drug Administration had granted ‘fast track’ status to its vaccine for the mosquito-borne Zika virus, which erupted as a major public hazard in Brazil three years ago.
The drug, TAK-426, is currently being tested on 240 patients between the ages of 18 and 49 and is in early stages of development. The virus might be responsible for an increase in birth defects in the United States and its territories, the U.S. Centers for Disease Control and Prevention said in a report last week.
The Zika outbreak was declared an international public health emergency by the World Health Organization in 2016 due to linkages found between the virus and severe birth defects.
The FDA’s ‘fast track’ designation aims to facilitate the development and expedite the review process for certain drugs and vaccines for serious conditions with unmet medical need.
Japan’s Takeda Pharmaceutical Co Ltd said on Monday the U.S. Food and Drug Administration had granted ‘fast track’ status to its vaccine for the mosquito-borne Zika virus, which erupted as a major public hazard in Brazil three years ago.
The drug, TAK-426, is currently being tested on 240 patients between the ages of 18 and 49 and is in early stages of development. The virus might be responsible for an increase in birth defects in the United States and its territories, the U.S. Centers for Disease Control and Prevention said in a report last week.
The Zika outbreak was declared an international public health emergency by the World Health Organization in 2016 due to linkages found between the virus and severe birth defects.
The FDA’s ‘fast track’ designation aims to facilitate the development and expedite the review process for certain drugs and vaccines for serious conditions with unmet medical need.
Japan’s Takeda Pharmaceutical Co Ltd said on Monday the U.S. Food and Drug Administration had granted ‘fast track’ status to its vaccine for the mosquito-borne Zika virus, which erupted as a major public hazard in Brazil three years ago.
The drug, TAK-426, is currently being tested on 240 patients between the ages of 18 and 49 and is in early stages of development. The virus might be responsible for an increase in birth defects in the United States and its territories, the U.S. Centers for Disease Control and Prevention said in a report last week.
The Zika outbreak was declared an international public health emergency by the World Health Organization in 2016 due to linkages found between the virus and severe birth defects.
The FDA’s ‘fast track’ designation aims to facilitate the development and expedite the review process for certain drugs and vaccines for serious conditions with unmet medical need.
Japan’s Takeda Pharmaceutical Co Ltd said on Monday the U.S. Food and Drug Administration had granted ‘fast track’ status to its vaccine for the mosquito-borne Zika virus, which erupted as a major public hazard in Brazil three years ago.
The drug, TAK-426, is currently being tested on 240 patients between the ages of 18 and 49 and is in early stages of development. The virus might be responsible for an increase in birth defects in the United States and its territories, the U.S. Centers for Disease Control and Prevention said in a report last week.
The Zika outbreak was declared an international public health emergency by the World Health Organization in 2016 due to linkages found between the virus and severe birth defects.
The FDA’s ‘fast track’ designation aims to facilitate the development and expedite the review process for certain drugs and vaccines for serious conditions with unmet medical need.
Japan’s Takeda Pharmaceutical Co Ltd said on Monday the U.S. Food and Drug Administration had granted ‘fast track’ status to its vaccine for the mosquito-borne Zika virus, which erupted as a major public hazard in Brazil three years ago.
The drug, TAK-426, is currently being tested on 240 patients between the ages of 18 and 49 and is in early stages of development. The virus might be responsible for an increase in birth defects in the United States and its territories, the U.S. Centers for Disease Control and Prevention said in a report last week.
The Zika outbreak was declared an international public health emergency by the World Health Organization in 2016 due to linkages found between the virus and severe birth defects.
The FDA’s ‘fast track’ designation aims to facilitate the development and expedite the review process for certain drugs and vaccines for serious conditions with unmet medical need.
Japan’s Takeda Pharmaceutical Co Ltd said on Monday the U.S. Food and Drug Administration had granted ‘fast track’ status to its vaccine for the mosquito-borne Zika virus, which erupted as a major public hazard in Brazil three years ago.
The drug, TAK-426, is currently being tested on 240 patients between the ages of 18 and 49 and is in early stages of development. The virus might be responsible for an increase in birth defects in the United States and its territories, the U.S. Centers for Disease Control and Prevention said in a report last week.
The Zika outbreak was declared an international public health emergency by the World Health Organization in 2016 due to linkages found between the virus and severe birth defects.
The FDA’s ‘fast track’ designation aims to facilitate the development and expedite the review process for certain drugs and vaccines for serious conditions with unmet medical need.
Japan’s Takeda Pharmaceutical Co Ltd said on Monday the U.S. Food and Drug Administration had granted ‘fast track’ status to its vaccine for the mosquito-borne Zika virus, which erupted as a major public hazard in Brazil three years ago.
The drug, TAK-426, is currently being tested on 240 patients between the ages of 18 and 49 and is in early stages of development. The virus might be responsible for an increase in birth defects in the United States and its territories, the U.S. Centers for Disease Control and Prevention said in a report last week.
The Zika outbreak was declared an international public health emergency by the World Health Organization in 2016 due to linkages found between the virus and severe birth defects.
The FDA’s ‘fast track’ designation aims to facilitate the development and expedite the review process for certain drugs and vaccines for serious conditions with unmet medical need.
Related posts:
W.H.O launches plan to fast-track COVID-19 vaccine
FG begs AfDB to fast-track $1bn loan
We’ll fast-track budget passage – Gbajabiamila
Lawmaker-elect Shina Peller promises to fast-track development
Clergyman urges govt to fast track decongestion of correctional centres
Sokoto Govt partners UK to fast track ICT development
My Policy Agenda Is To Fast Track Development In Ifako Ijaiye Constituency-Ayoola
Kaduna govt partners relevant stakeholders to fast-track SDGs
